Comparison of Respiratory Syncytial Virus (RSV)–Specific Antibody Durability in Pregnant/Postpartum Individuals and Older Adults After RSV Vaccination
Respiratory syncytial virus (RSV) vaccination is recommended in pregnancy. Limited data exist regarding antibody (Ab) durability to inform revaccination timing. We conducted prospective cohort studies among pregnant and older adults after first RSV vaccination in 2023-2024. Longitudinal samples from 50 pregnant (36 vaccinated) and 16 vaccinated older adults were collected until 12-15 months after vaccination and tested for RSV binding and neutralizing Ab. Mean Ab levels 12-15 months after vaccination were similar between vaccinated maternal and older adult participants (P = .73), suggesting Ab durability up to 1 year after maternal RSV vaccination. RSV binding and neutralizing Ab titers were strongly correlated (R = .73).
Authors
- Alisa Kachikis (ORCID: https://orcid.org/0000-0003-0358-5107)
- Sandra McAteer (ORCID: https://orcid.org/0000-0001-7220-4641)
- Jennifer E Stolarczuk (ORCID: https://orcid.org/0009-0008-6708-8170)
- Linda O. Eckert (ORCID: https://orcid.org/0000-0002-1357-8405)
- Erica Clark
- Marco Carone (ORCID: https://orcid.org/0000-0003-2106-0953)
- Jonathan C. Reed (ORCID: https://orcid.org/0000-0003-4425-7636)
- Clarice Mauer
- Kittredge McVey
- Grace Marshall
- Alex Harteloo
- Helen Y Chu
- Ioana Maria Saidac
- Mindy Pike
- Collrane Frivold
- Janet A Englund
- Alexander L Greninger
Institutions
- University of Washington (US)
- Seattle Children's Hospital (US)
- Seattle Institute for Biomedical and Clinical Research (US)
Publication Details
- Journal
- The Journal of Infectious Diseases
- Published
- 2026-03-26
- DOI
- https://doi.org/10.1093/infdis/jiag111
- Primary Topic
- Respiratory viral infections research
- Type
- article
- Field-Weighted Citation Impact
- 0.00